Literature DB >> 11989661

Angiogenesis and the unique nature of tumor matrix.

Vincenzo Chiarug1, Marco Ruggiero, Lucia Magnelli.   

Abstract

In this article we consider the factors responsible for the unique nature of the pericellular matrix of solid tumors and we discuss the role of alterations of tumor blood vessel structure. We examine the role of VEGF (vascular endothelial growth factor), a factor controlling permeability of capillaries, plasma protein extravasation, and the formation of a fibrin barrier. We discuss how this barrier could be destroyed by metalloproteinases bound on the surface of endothelial cells migrating through the matrix and how these enzymes are responsible for the activation of gelatinases that destroy basement membranes. The process called tubulogenesis, which gives rise to hyperpermeable tumor capillaries, will also be described. Alterations of the blood vessel structure leading to hypoxia of the matrix, and accumulation of plasma proteins and of blood cells will be treated. Finally, we review some of the strategies that might exploit this knowledge about the nature of the tumoral matrix for designing novel anticancer treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11989661     DOI: 10.1385/mb:21:1:085

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  35 in total

Review 1.  Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?

Authors:  G Murphy; V Knäuper
Journal:  Matrix Biol       Date:  1997-03       Impact factor: 11.583

Review 2.  The internal milieu of tumors.

Authors:  P M Gullino
Journal:  Prog Exp Tumor Res       Date:  1966

3.  Thrombin rapidly and efficiently activates gelatinase A in human microvascular endothelial cells via a mechanism independent of active MT1 matrix metalloproteinase.

Authors:  M Nguyen; J Arkell; C J Jackson
Journal:  Lab Invest       Date:  1999-04       Impact factor: 5.662

4.  Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.

Authors:  H Ueno; H Nakamura; M Inoue; K Imai; M Noguchi; H Sato; M Seiki; Y Okada
Journal:  Cancer Res       Date:  1997-05-15       Impact factor: 12.701

Review 5.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Authors:  J M Brown; A J Giaccia
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

Review 6.  Gangliosides, copper ions and angiogenic capacity of adult tissues.

Authors:  P M Gullino; M Ziche; G Alessandri
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

7.  Vascular permeability factor mRNA and protein expression in human kidney.

Authors:  L F Brown; B Berse; K Tognazzi; E J Manseau; L Van de Water; D R Senger; H F Dvorak; S Rosen
Journal:  Kidney Int       Date:  1992-12       Impact factor: 10.612

8.  The vascular pattern of basal cell tumors: light microscopy and scanning electron microscopic study on vascular corrosion casts.

Authors:  T W Grunt; A Lametschwandtner; O Staindl
Journal:  Microvasc Res       Date:  1985-05       Impact factor: 3.514

9.  Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature.

Authors:  M W Dewhirst; C Y Tso; R Oliver; C S Gustafson; T W Secomb; J F Gross
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-07       Impact factor: 7.038

10.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  8 in total

1.  Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro.

Authors:  Zhong-Ping Gu; Yun-Jie Wang; Yu Wu; Jin-Ge Li; Nong-An Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

2.  Value of fibrinogen and D-dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer.

Authors:  He-Guo Jiang; Jian Li; Shun-Bing Shi; Ping Chen; Li-Ping Ge; Qian Jiang; Xin-Ping Tang
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

3.  The Combination of Plasma Fibrinogen Concentration and Neutrophil Lymphocyte Ratio (F-NLR) as a Prognostic Factor of Epithelial Ovarian Cancer.

Authors:  Jiani Yang; Jun Ma; Shanshan Cheng; Yu Wang
Journal:  Onco Targets Ther       Date:  2020-07-27       Impact factor: 4.147

4.  Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells.

Authors:  Ganchimeg Ishdorj; James B Johnston; Spencer B Gibson
Journal:  BMC Cancer       Date:  2011-06-24       Impact factor: 4.430

5.  Prognostic significance of preoperative plasma D-dimer level in patients with surgically resected clinical stage I non-small cell lung cancer: a retrospective cohort study.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  J Cardiothorac Surg       Date:  2017-11-28       Impact factor: 1.637

6.  Elevated preoperative plasma D-dimer dose not adversely affect survival of gastric cancer after gastrectomy with curative intent: A propensity score analysis.

Authors:  Yuexiang Liang; Donglei He; Liangliang Wu; Xuewei Ding; Xiaona Wang; Baogui Wang; Rupeng Zhang; Han Liang
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

7.  Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer.

Authors:  Wuhao Huang; Shengguang Wang; Hua Zhang; Bin Zhang; Changli Wang
Journal:  Cancer Biol Med       Date:  2018-02       Impact factor: 4.248

8.  The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy.

Authors:  Yujing Huang; Bangjian Liu; Yuanjue Sun; Jianjun Zhang; Yang Yao; Aina He
Journal:  Oncotarget       Date:  2016-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.